	US 12,220,413 B2
	Magnetic nano-drug with double targeting VEGF-VEGFR, and preparation method and application thereof
Xin Liu, Nanjing (CN); Ran Kang, Nanjing (CN); Lin Xie, Nanjing (CN); Congyang Xue, Nanjing (CN); Bo Chen, Nanjing (CN); Zihan Wang, Nanjing (CN); Nan Wang, Nanjing (CN); and Liping Chen, Nanjing (CN)
Assigned to The Third Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing (CN)
Filed by The Third Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing (CN)
Filed on Jul. 8, 2024, as Appl. No. 18/765,361.
Claims priority of application No. 202310853646.3 (CN), filed on Jul. 11, 2023.
Prior Publication US 2025/0017920 A1, Jan. 16, 2025
Int. Cl. A61K 31/4965 (2006.01); A61K 9/51 (2006.01); A61K 38/44 (2006.01); A61K 41/00 (2020.01); A61K 47/60 (2017.01); A61K 47/69 (2017.01)

CPC A61K 31/4965 (2013.01) [A61K 9/5115 (2013.01); A61K 9/5169 (2013.01); A61K 38/443 (2013.01); A61K 41/0052 (2013.01); A61K 47/60 (2017.08); A61K 47/6923 (2017.08); C12Y 101/01027 (2013.01)]

5 Claims

1. A magnetic nano-drug with double targeting vascular endothelial growth factor (VEGF)-vascular endothelial growth factor receptor (VEGFR), comprising aminated zinc ferrite (ZnFe₂O₄) hollow porous magnetic nano-particles, ligustrazine hydrochloride nano-spheres lactate dehydrogenase-silk fibroin (LDH-SF), ethylene dichloride (EDC), and n-hydroxy succinimide (NHS), wherein the LDH-SF comprises silk fibroin (SF) and ligustrazine hydrochloride (LTH); and a mass ratio of the aminated ZnFe₂O₄hollow porous magnetic nano-particles to the EDC to the NHS to the LDH-SF is (5-10):(1-5):(1-6):(1-8).